The experimental compound, designated as DT-109, works through a multifaceted mechanism that involves suppressing harmful gut bacteria, reinforcing the delicate intestinal lining, and blocking inflammatory substances from migrating to the liver. According to findings published in The Journal of Clinical Investigation, this novel approach successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in both murine models and nonhuman primates, offering a potential lifeline for managing a complex and progressive disease.
MASH is a serious, aggressive subtype of metabolic dysfunction-associated steatotic liver disease that currently affects approximately 7% of the global population. The condition is characterized by an abnormal accumulation of excess fat within the liver tissue, which subsequently triggers persistent inflammation and cellular injury. Over time, if left unchecked, this ongoing damage can drive the disease forward into cirrhosis—a stage defined by extensive, irreversible liver scarring—as well as elevate the risks of developing primary liver cancer or total liver failure. Although modern medicine has made incremental strides in improving therapeutic options in recent years, highly effective treatments capable of safely managing or reversing advanced MASH remain sparse.
"We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression," said Eugene Chen, M.D., Ph.D., the senior author of the study and the Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School. "This compound shows benefits to the gastrointestinal system and has great potential as a treatment for MASH."
How Harmful Gut Bacteria Can Trigger Liver Damage
Prior to this latest breakthrough, Chen’s research laboratory had already demonstrated that DT-109, a glycine-based tripeptide, possessed the capacity to ameliorate MASH symptoms in animal studies. A tripeptide is fundamentally a small molecule constructed from three amino acids, which serve as the primary biochemical building blocks of proteins. However, the precise molecular pathways and mechanisms through which the compound produced its robust protective effects remained elusive to the scientific team.
The latest study provides a comprehensive explanation, detailing how alterations in the composition of gut bacteria can initiate a destructive biochemical chain reaction that ultimately damages the liver, and demonstrating precisely how DT-109 interrupts that pathological cascade.
Before analyzing the pharmacological impact of the drug, the investigators confirmed a critical underlying driver of MASH: the overgrowth of Clostridium perfringens, a pathogenic bacterium known for generating high levels of ammonia inside the intestinal lumen. When local concentrations of ammonia rise abnormally, they begin to compromise and degrade the gut’s protective inner lining. Under normal, healthy physiological conditions, this robust intestinal epithelial barrier acts as a vigilant gatekeeper, preventing potentially toxic substances and microbial byproducts from escaping the digestive tract and entering the systemic circulation.
As this vital barrier weakens, however, toxins, bacterial metabolites, and other inflammatory antigens generated by gut microbes gain unauthorized passage into the bloodstream. Once these substances travel to the liver via the portal circulation, they provoke intense inflammation and hyperactivate local immune defenses, compounding cellular stress and accelerating tissue injury.
One of the primary immune responses triggered by this influx involves the excessive activation of CD8+ T cells. While these specialized immune cells normally play a critical role in helping the human body identify and destroy virus-infected or abnormal cells, their chronic overactivation within a compromised metabolic environment heavily contributes to the destructive inflammatory processes characteristic of MASH. These findings help clarify why a pathological condition historically viewed as centering entirely on the liver can be powerfully influenced by distant biochemical events occurring within the gastrointestinal tract.
Experimental Drug Repairs the Gut and Protects the Liver
Through a meticulous sequence of experimental trials, the research team discovered that DT-109 effectively disrupts this destructive cycle by rehabilitating the intestinal microenvironment and structurally reinforcing the gut’s protective barrier.
In both murine models and nonhuman primates, administration of the compound successfully reduced populations of Clostridium perfringens and lowered luminal ammonia production within the intestines. These positive microbial and chemical shifts helped fortify the integrity of the intestinal lining, tightly restricting the systemic translocation of harmful microbial substances into the broader body and mitigating their capacity to inflict damage on hepatic tissue.
The therapeutic results were particularly striking in nonhuman primates, whose underlying liver physiology, metabolism, and gut microbial ecosystems bear a much closer resemblance to human biology than those of mice. In these higher-order animal models, DT-109 visibly reduced intrahepatic inflammation and lessened the overall clinical severity of MASH.
Taken together, these empirical findings illustrate how intervening in harmful pathophysiological processes within the gut can yield profound downstream benefits inside the liver, even though the primary pharmacological action of the drug occurs largely within the boundaries of the gastrointestinal system.
"DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis," said Jifeng Zhang, Ph.D., co-author and research professor of cardiovascular medicine at the U-M Medical School. "We also found that DT-109 primarily acts in the gastrointestinal tract, but its reach stretches much further."
The gut-liver axis describes the intimate and continuous biological crosstalk connecting the digestive system and the liver. Because nutrients and chemical substances absorbed from the intestines are funneled directly to the liver through the hepatic portal system, overall liver health is exquisitely sensitive to fluctuations in gut microbial populations and the functional integrity of the intestinal barrier. By strategically targeting this physiological bridge, DT-109 provides a novel mechanism to interrupt the core drivers of liver inflammation rather than merely attempting to manage or treat tissue damage after it has already occurred.
Potential Benefits Beyond Fatty Liver Disease
Given its demonstrated ability to safeguard the intestinal barrier and regulate systemic inflammation, researchers believe the compound’s clinical utility could extend far beyond fatty liver disease, potentially offering therapeutic value against other chronic conditions driven by metabolic dysfunction and systemic inflammation.
Earlier investigations led by the same team revealed that DT-109 can significantly reduce the formation of atherosclerotic plaques and halt vascular calcification in nonhuman primates. Atherosclerotic plaques consist of pathological deposits of cholesterol, fat, and cellular waste that accumulate within the inner walls of arteries, gradually constricting blood flow and drastically elevating the risk of cardiovascular events such as heart attacks and strokes. Vascular calcification, meanwhile, occurs when calcium deposits harden within blood vessel walls, stripping them of elasticity and further compounding cardiovascular disease risk.
The intersection of these findings suggests that DT-109 could eventually be harnessed to treat both hepatic and cardiovascular disorders simultaneously—an encouraging prospect given that metabolic syndromes frequently manifest as multi-organ diseases affecting both the liver and the vascular network.
Furthermore, the research team is currently exploring whether the compound might offer clinical benefits for patients suffering from inflammatory bowel disease (IBD), a broad classification of chronic gastrointestinal disorders that includes Crohn’s disease and ulcerative colitis. Because structural and functional breakdowns of the intestinal barrier are hallmark features shared across multiple gastrointestinal pathologies, a therapeutic agent capable of restoring barrier integrity could theoretically provide systemic advantages well beyond liver protection. Nonetheless, rigorous additional studies will be required to formally evaluate whether DT-109 can safely and effectively target these separate conditions.
A Promising Treatment That Still Needs Human Trials
Despite the overwhelmingly encouraging outcomes observed in preclinical investigations, DT-109 remains an experimental therapeutic agent. While its remarkable capacity to reverse MASH has been firmly established in animal models, scientists have yet to determine whether the compound can safely, predictably, and effectively replicate these positive health outcomes in human patients.
The next critical phase of the research initiative will involve comprehensive preclinical evaluations and toxicological assessments, with the ultimate objective of advancing the compound into formal human clinical trials. These upcoming studies will be indispensable for establishing proper dosing, confirming human safety profiles, and verifying therapeutic efficacy in individuals living with advanced metabolic liver disease.
"This study presents novel evidence about the pathogenesis of MASH and provides excitement about a therapeutic avenue to explore for a condition that remains difficult to treat," said Elliot Tapper, M.D., Academic Director of Hepatology at Michigan Medicine. "What patients with MASH need is a safe and effective therapy capable of improving their liver and heart health—of course we are excited about these developments."
This scientific discovery marks a notable paradigm shift in how researchers conceptualize and approach the treatment of fatty liver disease. By shifting focus toward the remediation of harmful gut bacteria and the restoration of the intestinal epithelial barrier, medical science may soon be able to protect vital internal organs using therapies that exert their primary biochemical effects outside the organs themselves.
Should future human clinical trials validate the robust benefits observed throughout animal testing, DT-109 could eventually emerge as a transformative therapeutic option for millions of patients battling severe fatty liver disease, while concurrently offering protection against dangerous cardiovascular complications.
The research was supported by institutional funding and collaborative efforts across multiple academic and clinical centers. Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen are named as inventors on a pending patent application covering tripeptides and their use in treating metabolic, cardiovascular, and inflammatory disorders. Chen is also recognized as an original inventor of DT-109. The University of Michigan holds the intellectual property rights for the compound and has licensed it to Diapin Therapeutics. Both Chen and the university retain financial ownership interests in Diapin, which supplied the DT-109 compound utilized in the study and is actively managing its ongoing clinical development.
All clinical protocols involving human data, including amendments and informed consent documentation, secured formal ethical approval from the Institutional Review Boards at participating medical centers, including the First Affiliated Hospital of Xi’an Jiaotong University, the Institutional Review Board of Jinan University, and the University of Hong Kong/Hospital Authority Hong Kong West Cluster. All animal research protocols involving nonhuman primates and murine models were strictly reviewed and authorized by the respective laboratory animal care and institutional oversight committees, adhering strictly to the guidelines outlined in the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
